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ABSTRACT
Aims/Introduction: Peroxisome proliferator-activated receptor-a (PPARa) is a therapeu-
tic target for hyperlipidemia. K-877 is a new selective PPARa modulator (SPPARMa) that
activates PPARa transcriptional activity. The aim of the present study was to assess the
effects of K-877 on lipid metabolism in vitro and in vivo compared with those of classical
PPARa agonists.
Materials and Methods: To compare the effects of K-877 on PPARa transcriptional
activity with those of the classical PPARa agonists Wy14643 (Wy) and fenofibrate (Feno),
the cell-based PPARa transactivation luciferase assay was carried out. WT and Ppara-/-
mice were fed with a moderate-fat (MF) diet for 6 days, and methionine–choline-deficient
(MCD) diet for 4 weeks containing Feno or K-877.
Results: In luciferase assays, K-877 activated PPARa transcriptional activity more effi-
ciently than the classical PPARa agonists Feno and Wy. After being fed MF diet containing
0.001% K-877 or 0.2% Feno for 6 days, mice in the K-877 group showed significant
increases in the expression of Ppara and its target genes, leading to marked reductions in
plasma triglyceride levels compared with those observed in Feno-treated animals. These
K-877 effects were blunted in Ppara-/- mice, confirming that K-877 activates PPARa. In fur-
ther experiments, K-877 (0.00025%) and Feno (0.1%) equally improved the pathology of
MCD diet-induced non-alcoholic fatty liver disease, with increased expression of hepatic
fatty acid oxidation genes.
Conclusions: The present data show that K-877 is an attractive PPARa-modulating
drug and can efficiently reduce plasma triglyceride levels, thereby alleviating the dysregu-
lation of lipid metabolism.
INTRODUCTION
Impaired nutrient homeostasis is a common characteristic of
metabolic disorders, such as obesity, diabetes, cardiovascular
diseases and fatty liver disease. Nutrient homeostasis is tightly
regulated through the balance between energy-producing path-
ways, such as ketogenesis, gluconeogenesis and lipid synthesis,
and energy utilization pathways, such as lipid oxidation.
Because of the emerging epidemic of obesity and diabetes, the
factors determining progression of non-alcoholic fatty liver
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disease (NAFLD) present a major clinical challenge. In particu-
lar, fatty liver can progress to non-alcoholic steatohepatitis
(NASH) after overwhelming of the adaptive mechanisms that
mediate lipid partitioning and metabolism, and protect hepato-
cytes from lipotoxicity of excess fatty acids (FAs) and other
lipids, resulting in inﬂammation and ﬁbrosis.
Peroxisome proliferative-activated receptors (PPARs) are
members of the nuclear receptor superfamily, and include
PPARa, PPARb/d and PPARc. On ligand binding, PPARs
form heterodimers with the retinoid X receptor, and interact
with PPAR response elements to regulate target gene expres-
sion. PPARa is most prominently expressed in the liver, and is
activated by hypolipidemic ﬁbrate-class drugs (ﬁbrates). PPARa
controls lipid ﬂux in the liver by modulating FA transport and
b-oxidation, and improves plasma lipid proﬁles by decreasing
triglyceride (TG) levels and increasing high-density lipoprotein
cholesterol levels. In addition, PPARa activation inhibits inﬂam-
matory genes that are induced by nuclear factor-jB, and
decreases the expression of acute-phase response genes. Accord-
ingly, PPARa deﬁciency increases susceptibility to NAFLD,
NASH, hepatic inﬂammation and acute phase responses1.
Fibrates, such as gemﬁbrozil, bezaﬁbrate, and fenoﬁbrate
(Feno), decrease plasma TG levels, and increase high-density
lipoprotein cholesterol levels in patients with hyperlipidemia
and type 2 diabetes, and can prevent coronary heart disease
and stroke2–6. However, these drugs are weak agonists of
PPARa, have poor substrate selectivity and require high clinical
doses. Therefore, a potent and selective PPARa agonist is
required for patients with metabolic syndrome. K-877 is a novel
selective PPARa modulator (SPPARMa) that enhances PPARa
activity7; it also elicits higher PPARa activation than other
ﬁbrates, with lower EC50 values and higher PPAR subtype
selectivity8.
In the present study, we compared the effects of K-877 on
lipid metabolism and hepatic gene expression related to NASH/
NAFLD with the classical PPARa agonists, Feno and Wy14643
(Wy), in vitro and in vivo.
MATERIALS AND METHODS
Reagents
K-877 was kindly provided by Kowa Co. Ltd. Feno and Wy
were purchased from Sigma-Aldrich (St. Louis, Missouri, USA).
Animals
Eight-week-old male C57BL/6J (wild-type; WT) mice were
obtained from CLEA Japan (Tokyo, Japan). B6;129S4-
Pparatm1Gonz/J (Ppara-/-) mice were purchased from the Jackson
Laboratory (Bar Harbor, Maine, USA). Methionine–choline-
deﬁcient (MCD)-diet analyses were carried out on 8-week-old
male mice that were fed for 4 weeks and killed without fasting.
All animal husbandry procedures and experiments were com-
pliant with the University of Tsukuba’s Regulations for Animal
Experiments, and were approved by the Animal Experiment
Committee at the University of Tsukuba.
Histological analysis
Harvested livers were ﬁxed, embedded in parafﬁn, sectioned
and stained with hematoxylin–eosin.
Plasmids
The expression vector for the Gal4-PPARa (pM Gal4-
PPARa) fusion protein was generated by inserting a human
PPARa fragment (166–468 aa) downstream of Gal4 in the
pM vector (Clontech, Palo Alto, California, USA). The GAL4
UAS–LUC vector contains eight copies of the UAS Gal4-
binding site9.
Cell culture
Mouse AML12.2 hepatoma cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium/Ham’s F12 media supplemented with
ITS Liquid Media Supplement (Sigma-Aldrich), 100 U/mL
penicillin, 100 lg/mL streptomycin and 10% fetal bovine
serum. Cells were incubated with Feno (50 lmol/L) or K-877
(5 and 50 lmol/L) for 48 h.
Transfections and Luc assays
HepG2 cells were grown at 37°C in an atmosphere of 5% CO2
in Dulbecco’s modiﬁed Eagle’s medium containing 25 mmol/L
glucose, 100 U/mL penicillin, 100 lg/mL streptomycin and
10% fetal bovine serum. Transfection studies were carried out
in cells on 24-well plates. Cells were transfected with pM Gal4-
PPARa DBD and GAL4 UAS luciferase vectors9, and a pRL-
SV40 plasmid as a reference (Promega, Madison, Wisconsin,
USA) using X-tremeGENE 9 (Roche, Basel, Switzerland). After
24 h of transfection, Wy (50 lmol/L), Feno (30 lmol/L) or K-
877 (50 nmol/L) were added to the medium. After additional
24-h incubation, ﬁreﬂy luciferase activity was measured and
normalized to that of Renilla.
Metabolic measurements
Plasma levels of TG, non-esteriﬁed FA (NEFA), total cholesterol
(TC), aspartate aminotransferase, alanine aminotransferase, and
liver TG and TC levels were measured as described previously10.
Analysis of gene expression
Total ribonucleic acid from cells and tissues was prepared using
a Trizol reagent (Invitrogen, Carlsbad, California, USA). Before
real-time polymerase chain reaction analyses, total ribonucleic
acid was reversed transcribed into complementary deoxyribonu-
cleic acid using a reverse transcriptase according to the manu-
facturer’s instructions (Invitrogen). Real-time polymerase chain
reaction was carried out using an ABI Prism 7300 system (ABI,
Carlsbad, California, USA) with TaqMan probes (Invitrogen)
and a SYBR Green Master Mix (Roche)11. Primer sequences
are available on request.
Statistical analysis
Comparisons of treatment groups were made using Tukey–Kra-
mer post-hoc tests, and differences were considered signiﬁcant
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when P < 0.05. All data are expressed as mean – standard
error of the mean.
RESULTS
K-877 effectively activates PPARa transcriptional activity
To compare the effects of K-877 on PPARa transcriptional activ-
ity with those of the classical PPARa agonists Wy and Feno,
cell-based transactivation assays were carried out using a Gal4-
luciferase assay system. After co-transfecting human HepG2 hep-
atoma cells with pM-GAL4 PPARa ligand-binding domain and
GAL4 UAS reporter vectors, cells were treated with K-877 for
24 h. Although K-877, Wy and Feno induced PPARa luciferase
activation in a dose-dependent manner, the dose–response curve
of K-877 was shifted to the left side compared with those of
Wy14643 and Feno (Figure 1a). K-877 is a highly potent agonist
of PPARa transcriptional activity, with half-maximal effective
concentrations (EC50) of 0.49 nmol/L. The PPARa agonists, Wy
(50 lmol/L), Feno (30 lmol/L) or K-877 (50 nmol/L) were trea-
ted for 24 h. PPARa luciferase activation by K-877 was compara-
ble with that by Wy or Feno (Figure 1b). Considering the
relative concentrations of these drugs, results show that K-877
activates the PPARa transcription activity more effectively than
the other agents. To determine the effects of K-877 on ﬁbroblast
growth factor 21 (Fgf21) expression, a typical target gene of
PPARa, in vitro, mouse AML12.2 hepatoma cells were incubated
with the PPARa agonists, Feno (50 lmol/L) or K-877 (5 and
50 lmol/L) for 48 h based on a previous report12. Both doses of
K-877 signiﬁcantly increased Fgf21 expression, but the increase
in expression by Feno was slight (Figure 1c). Thus, K-877 can
efﬁciently activate Fgf21 expression.
K-877 decreased plasma lipid levels in WT mice
Based on a previous report7, 8-week-old male WT mice were
fed a moderate-fat (MF) diet containing 0.2% (w/w) Feno or
0.001% (w/w) K-877 for 6 days. Although the dose of K-877
was 200-fold lower than that of Feno, compared with no treat-
ment, K-877 and Feno signiﬁcantly reduced plasma TG levels,
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(a) Figure 1 | K-877 activates the Peroxisome proliferator-activated
receptor-a (PPARa) transcriptional activity. (a,b) HepG2 cells were co-
transfected with GAL4 UAS-LUC and pM GAL4-hPPARa ligand-binding
domain vectors, and with a pRL-SV40 plasmid as a reference in 24-well
plates for 24 h. Cells were then treated with Wy, Feno or K-877 for
48 h, and were harvested at 48 h after transfection. Luciferase activity
was measured and normalized to that of Renilla luciferase activity. (a)
Dose–response curves of PPARa transactivation. (b) Cells were then
treated with Wy14643 (Wy; 50 μmol/L), fenofibrate (Feno; 30 μmol/L)
or K-877 (50 nmol/L); n = 8 per group. (c) AML12.2 cells were treated
with Feno (50 μmol/L) or K-877 (5 and 50 μmol/L) for 48 h. Fgf21
expression was determined by quantitative polymerase chain reaction;
n = 9 per group, *P < 0.05 and **P < 0.01.
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and tended to reduce TC and NEFA levels (Figure 2a), and the
effects of both agonists were blunted in Ppara-/- mice (Fig-
ure 2a). These data show that considering the concentrations of
agonists, K-877 elicits greater PPARa-mediated lipid-lowering
effects than Feno. Accordingly, hepatic gene expression of
Ppara and its target genes, such as those encoding cyclic adeno-
sine monophosphate responsive element binding protein 3-like
3 (Creb3l3), Fgf21, acyl-CoA oxidase 1, palmitoyl (Acox1) and
carnitine palmitoyltransferase 1a, liver (Cpt1a), were signiﬁ-
cantly increased by both PPARa agonists (Figure 2b). These
changes in gene expression were similar in the presence of K-
877 and Feno despite dose differences, showing that K-877 has
more powerful effects on PPARa activation than Feno. In addi-
tion, the effects of both agonists were abolished in Ppara-/-
mice, conﬁrming that these agonists target the PPARa
pathway.
K-877 suppresses MCD-induced liver injury in normal mice,
but not in Ppara-/- mice
To compare the effects of PPARa agonists on the progression
of NAFLD, WT and Ppara-/- mice were fed an MCD diet con-
taining 0.1% Feno or 0.00025% K-877 for 4 weeks, and their
optimum doses were determined according to previously
reported methods7,12. This diet has been used extensively to
produce diet-induced animal models of NASH that show simi-
lar histology to that of human NASH1. Histological analyses of
hematoxylin–eosin-stained liver sections from WT mice showed
that the MCD diet led to slight lipid accumulation in hepato-
cytes (Figure 3a). The addition of Feno and K-877 suppressed
MCD-induced lipid accumulation (Figure 3a). Furthermore,
sections from MCD-fed Ppara-/- mice showed greater lipid
accumulation and macrophage invasion than those from
MCD-fed WT mice, but the addition of Feno and K-877 could
not improve them (Figure 3a). Hepatic TG and TC contents
were signiﬁcantly increased in MCD diet-fed mice than in MF
diet-fed mice (Figure 3b). The addition of K-877 and Feno into
MCD diets tended to reduce liver TG and TC levels, and
Ppara-/- mice showed more severe liver lipid accumulation
than WT mice (Figure 3b). However, PPARa agonists did not
improve these phenotypes signiﬁcantly (Figure 3b). In further
analyses, increased plasma alanine aminotransferase and aspar-
tate aminotransferase levels were observed in MCD diet-fed
WT mice, compared with those in MF diet-fed WT mice (Fig-
ure 3c). The administration of K-877 or Feno tended to
decrease MCD diet-induced alanine aminotransferase and
aspartate aminotransferase levels. However, both agonists failed
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Figure 2 | K-877 reduces plasma lipid levels and increases the expression of hepatic fatty acid oxidation genes in wild type, but not in Ppara-/-
mice. Eight-week old male wild-type (WT) and Ppara-/- mice were administrated with fenofibrate (Feno; 0.2%) or K-877 (0.001%) for 6 days. (a)
Plasma triglyceride, total cholesterol and non-esterified fatty acid (NEFA) levels, and (b) hepatic gene expression in WT and Ppara-/- mice; n = 9–13
per group; *P < 0.05 and **P < 0.01. mRNA, messenger ribonucleic acid.
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to suppress these increases in Ppara-/- mice (Figure 3c). Taken
together, these data suggest that K-877 and Feno ameliorate
MCD diet-induced fatty liver progression.
K-877 activates PPARa target gene expression and reduces
Xbp1s expression in the liver of MCD-fed mice
Hepatic gene expression was determined in WT and Ppara-/-
mice after feeding on a MCD diet containing PPARa agonists for
4 weeks. Consistent with the expression levels of Ppara and its
target genes Creb3l3 in normal mice, Acox1 and Cpt1a were sig-
niﬁcantly increased to similar levels in the presence of PPARa
agonists (Figure 4). However, Fgf21 expression was decreased in
the presence of PPARa agonists. Furthermore, no apparent dif-
ferences in inﬂammatory and macrophage hepatic gene expres-
sion were observed between MCD diet-fed WT mouse groups.
The administration of PPARa agonists on Ppara-/- mice showed
increased Cd68 expression, supporting the increase of macro-
phages including Kupffer cells. However, the MCD diet induced
endoplasmic reticulum (ER) stress markers, such as X-box bind-
ing protein 1s (Xbp1s) in WT mice. In addition, the effects of
K-877 on Xbp1s expression were abolished in Ppara-/- mice. In
subsequent experiments, K-877 suppressed MCD diet-induced
Xbp1s expression more efﬁciently than Feno, thereby ameliorat-
ing ER stress in MCD diet-fed WT mice. In contrast, neither
PPARa agonist suppressed ER stress-related gene expression in
Ppara-/-mice. These data show that K-877 increases PPARa tar-
get genes that are related to FA oxidation and reduces Xbp1s
expression, leading to decreased liver injury.
DISCUSSION
In the present study, we showed that K-877 speciﬁcally and efﬁ-
ciently activates PPARa transactivation activity in vitro and
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Figure 3 | K-877 suppresses methionine–choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease in wild-type (WT), but not in Ppara-/-
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for 4 weeks. Hematoxylin–eosin staining in the (a) liver, (b) hepatic lipid contents, and (c) plasma aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels were determined in WT and Ppara-/- mice; n = 5–10 per group, *P < 0.05 and **P < 0.01. TC, total cholesterol; TG,
triglyceride.
450 J Diabetes Investig Vol. 8 No. 4 July 2017 ª 2017 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
O R I G I N A L A R T I C L E
Takei et al. http://onlinelibrary.wiley.com/journal/jdi
in vivo. Furthermore, K-877 had greater lipid-lowering effects
than the classical PPARa agonists in mice, and signiﬁcantly
induced PPARa target genes. These effects reduced MCD-
induced liver injury by increasing PPARa target gene expression
and decreasing ER stress in the liver. Therefore, K-877 might be
an effective drug for hyperlipidemia.
Fibrates are widely used to ameliorate the macro- and
microvascular risks associated with metabolic syndrome. How-
ever, these agents are weak PPARa agonists, and have limited
efﬁcacy due to dose-related adverse events. To address this
problem, a new generation of PPARa-speciﬁc agonists, known
as SPPARMas, has been developed to maximize receptor-
mediated effects and diminish side effects. In luciferase analyses,
we conﬁrmed that K-877 activates PPARa at 1,000-fold lower
doses than Feno and Wy. K-877 increases Fgf21 expression, one
of the typical target genes for PPARa in AML12.2 cells. FGF21
is known to ameliorate obesity, diabetes and hyperlipidemia by
inducing lipid catabolism13,14. The in vivo studies showed that
K-877 and Feno induced the PPARa target genes, Fgf21, Acox1
and Cpt1a, in the liver of MF-fed WT mice, suggesting that
these compounds activate hepatic FA oxidation. These effects
were similar in the presence of low doses of K-877, or high
doses of Feno, suggesting superiority of K-877 as a clinical
agent. As a result, the administration of K-877 and Feno in MF-
fed WT mice reduced plasma lipids, including TG, TC and
NEFA. Previous reports have shown that some PPARa agonists
prevent the progression of NAFLD15,16. Accordingly, K-877 efﬁ-
ciently increased the PPARa transcriptional activity and subse-
quently transactivated FA oxidation genes, including Acox1 and
Cpt1a, resulting in reduced hepatic lipid accumulation in MCD-
fed mice. However, Fgf21 expression was decreased in MCD-fed
WT mice in the presence of PPARa agonist compared with that
in MCD-fed WT mice without agonists. Fgf21 expression was
induced in both WT and Ppara-/- mice in response to MCD,
suggesting that a PPARa independent mechanism underlies
MCD-induced Fgf21 expression.
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ER stress is associated with an accumulation of misfolded
and unfolded proteins in the ER lumen. ER plays an essential
role in controlling lipid metabolism. XBP1s induces the expres-
sion of multiple inﬂammatory cytokines17, suggesting important
roles of ER stress in the pathology of NAFLD. K-877 reduced
hepatic Xbp1s expression, indicating potential roles in the man-
agement of ER stress. Furthermore, reduced lipid accumulation
in the presence of K-877 might lead to decreases in the ER
stress-related gene expression. Finally, the effects of K-877 in
Ppara-/- mice were blunted, conﬁrming that this agonist specif-
ically targets PPARa.
Selective activation of PPARa by K-877 was associated with
beneﬁcial changes in liver disease markers, suggesting the
potential of this novel agent in the treatment of NASH/NAFLD
might relate to PPARa pathway activation and reduced ER
stress. However, the mechanisms of K-877-mediated PPARa
activation remain unknown, warranting further studies to char-
acterize the speciﬁcity of K-877 for PPARa activation, recruit-
ment of cofactors, and downstream gene expression.
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